The mission of the Systems and Computational Biology Core (SCB) is to provide technology resources and support services in systems and computational biology for KCI members, and to promote collaborative research in systems-based oncology across all five Programs. To accomplish this mission, SCB activities are focused in the areas of: 1) workflow planning and experimental design of studies in functional genomics, genetic variation, and cancer systems biology;2) analysis and interpretation of gene expression profiling data (e.g., oncogenomic signatures);3) analysis and modeling of genotype profiling data from both population studies of inherited cancer risk factors and from molecular studies of somatic variation in individual tumors;4) pathway and network modeling of high throughput (""""""""omics"""""""") data for biomarker and drug target discovery;and 5) database management and integration of functional genomics and genotype data for clinical translational oncology (e.g., deployment of NCI caBIG? tools). In particular, SCB activities enable the application of molecular profiling and network modeling approaches to clinical studies ranging from the molecular to the population level. The key service lines for the SCB provide an integrated workflow pipeline for all stages of a systems-based project, from pre-project planning and experimental design through post-experiment data analysis and interpretation. Consultation and user training are key components of SCB's approach to lowering the technology barrier for KCI members who wish to incorporate computational analytics and molecular profiling tools into their research projects.
The Systems and Computational Biology Core provides integrative capabilities that support the translation of results from basic research in cancer biology into practical clinical applications for the diagnosis, prognosis and therapy of cancer as a systemic disease.
|Hamel, Lauren M; Penner, Louis A; Albrecht, Terrance L et al. (2016) Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer. Cancer Control 23:327-337|
|Xie, Yuran; Kim, Na Hyung; Nadithe, Venkatareddy et al. (2016) Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release 229:120-9|
|Cheriyan, Vino T; Muthu, Magesh; Patel, Ketan et al. (2016) CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers. Oncotarget :|
|Moorman, Patricia G; Alberg, Anthony J; Bandera, Elisa V et al. (2016) Reproductive factors and ovarian cancer risk in African-American women. Ann Epidemiol 26:654-62|
|Najor, Nicole A; Weatherford, Layne; Brush, George S (2016) Prevention of DNA Rereplication Through a Meiotic Recombination Checkpoint Response. G3 (Bethesda) 6:3869-3881|
|Herroon, Mackenzie Katheryn; Diedrich, Jonathan Driscoll; Podgorski, Izabela (2016) New 3D-Culture Approaches to Study Interactions of Bone Marrow Adipocytes with Metastatic Prostate Cancer Cells. Front Endocrinol (Lausanne) 7:84|
|Gimotty, Phyllis A; Shore, Ronald; Lozon, Nancy L et al. (2016) Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications. J Invest Dermatol 136:2168-2172|
|Ekanger, Levi A; Polin, Lisa A; Shen, Yimin et al. (2016) Evaluation of Eu(II) -based positive contrast enhancement after intravenous, intraperitoneal, and subcutaneous injections. Contrast Media Mol Imaging 11:299-303|
|Divi, Vasu; Harris, Jonathan; Harari, Paul M et al. (2016) Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer :|
|Katz, Matthew H G; Shi, Qian; Ahmad, Syed A et al. (2016) Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg 151:e161137|
Showing the most recent 10 out of 634 publications